More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/alpha-Cyano-4-hydroxycinnamic acid [28166-41-8]
Chemical Structure
Chemical Structure
Chemical Structure

alpha-Cyano-4-hydroxycinnamic acid [28166-41-8]

Research Use Only
AG-CR1-3686
AdipoGen Life Sciences
Estimated Purity>98%
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Molecular Weight189.2
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    alpha-Cyano-4-hydroxycinnamic acid [28166-41-8]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C10H7NO3
  • Molecular Weight
    189.2
  • Scientific Description
    Chemical. CAS: 28166-41-8. Formula: C10H7NO3. MW: 189.2. . Specific monocarboxylate transporter (MCT) inhibitor. Inhibits mitochondrial lactate and pyruvate transport. Decreases glycolysis. Useful agent for immunometabolism research. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration and invasion. Blocks lactate efflux from glioma cells and sensitizes cells to irradiation. Highly malignant tumors rely heavily on aerobic glycolysis (metabolism of glucose to lactic acid even under presence of oxygen; Warburg Effect) and thus need to efflux lactic acid via MCTs to the tumor micro-environment to maintain a robust glycolytic flux and to prevent the tumor from apoptosis. Inhibiting lactic acid efflux is a very effective therapeutic strategy against highly glycolytic malignant tumors. Common organic matrix-assisted laser desorption/ionization (MALDI) matrix. - Specific monocarboxylate transporter (MCT) inhibitor. Inhibits mitochondrial lactate and pyruvate transport. Decreases glycolysis. Useful agent for immunometabolism research. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration and invasion. Blocks lactate efflux from glioma cells and sensitizes cells to irradiation. Highly malignant tumors rely heavily on aerobic glycolysis (metabolism of glucose to lactic acid even under presence of oxygen; Warburg Effect) and thus need to efflux lactic acid via MCTs to the tumor micro-environment to maintain a robust glycolytic flux and to prevent the tumor from apoptosis. Inhibiting lactic acid efflux is a very effective therapeutic strategy against highly glycolytic malignant tumors. Common organic matrix-assisted laser desorption/ionization (MALDI) matrix.
  • SMILES
    OC1=CC=C(/C=C(C#N)/C(O)=O)C=C1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle: G.A. Brooks, et al.; PNAS 96, 1129 (1999)
  • Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition: A.R. Diers, et al.; Biochem. J. 444, 561 (2012)
  • The monocarboxylate transporter inhibitor alpha-cyano-4-hydroxycinnamic acid disrupts rat lung branching: S. Granja, et al.; Cell Physiol. Biochem. 32, 1845 (2013)
  • A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)
  • Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors: G. Andrejeva & J.C. Rathmell; Cell Metab. 26, 49 (2017)
  • Metabolic Instruction of Immunity: M.D. Buck, et al.; Cell 169, 570 (2017)